Secondary osteoporosis: underlying disease and the risk for glucocorticoid-induced osteoporosis (Q35680541)

9 August 2017

1 reference

title

Secondary osteoporosis: underlying disease and the risk for glucocorticoid-induced osteoporosis (English)

1 reference

glucocorticoid-induced osteoporosis

9 August 2017

0 references

1 reference

Eugene P Boling

1

1 reference

9 August 2017

1 January 2004

1 reference

9 August 2017

Clinical Therapeutics

1 reference

9 August 2017

26

1 reference

9 August 2017

1

1 reference

9 August 2017

1-14

1 reference

Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study

9 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Rates of cancellous bone remodeling and turnover in osteopenia associated with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn's disease and ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

High prevalence of osteoporotic vertebral fractures in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Low-dose corticosteroid therapy in rheumatoid arthritis: balancing the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Steroid-induced osteoporosis in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Chronic glucocorticoid therapy-induced osteoporosis in patients with obstructive lung disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Pathogenesis and treatment of glucocorticoid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Glucocorticoid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Use of oral corticosteroids and risk of fractures.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Glucocorticoid osteoporosis--mechanisms and management

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Steroid-induced fractures and bone loss in patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Glucocorticoid-Induced Osteoporosis: Pathogenesis and Management

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Oral corticosteroids and fracture risk: relationship to daily and cumulative doses

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Corticosteroid-induced bone loss. A longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computed tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Prevention and treatment of glucocorticoid-induced osteoporosis. A pathogenetic perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Asthma and chronic obstructive airway diseases are associated with osteoporosis and fractures: a literature review.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Safety of inhaled and intranasal corticosteroids: lessons for the new millennium

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Bone mineral density in women with asthma on long-term inhaled corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Establishing a therapeutic index for the inhaled corticosteroids: part II. Comparisons of systemic activity and safety among different inhaled corticosteroids.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Bone mineral density in subjects with mild asthma randomised to treatment with inhaled corticosteroids or non-corticosteroid treatment for two years

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Inhaled corticosteroid use and bone-mineral density in patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Effects of inhaled glucocorticoids on bone density in premenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Not all postmenopausal women on chronic steroid and estrogen treatment are osteoporotic: predictors of bone mineral density

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Guidelines on the management of osteoporosis associated with chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Osteoporosis and skeletal fractures in chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Management of osteoporosis in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Prevalence and prediction of osteopenia in chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Low body mass index and use of corticosteroids, but not cholestasis, are risk factors for osteoporosis in patients with chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Low bone mineral density in patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Osteoporosis and determinants of bone density in patients with Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

The pathophysiology of bone disease in gastrointestinal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Bone mineral density and calcium regulating hormones in patients with inflammatory bowel disease (Crohn's disease and ulcerative colitis)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Relationships between vitamin D, parathyroid hormone and bone mineral density in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Glucocorticosteroids in the management of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Rheumatoid arthritis, corticosteroid therapy and hip fracture

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Spontaneous production of bone-resorbing lymphokines by B cells in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Longitudinal analysis of bone mineral density in pre-menopausal female systemic lupus erythematosus patients: deleterious role of glucocorticoid therapy at the lumbar spine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Increased risk of hip fracture among patients with end-stage renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Risk factors for reduced bone density in haemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Prevalence and risk factors for osteopenia in dialysis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Disturbances of acid-base balance and bone disease in end-stage renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Short-term effect of vitamin K administration on prednisolone-induced loss of bone mineral density in patients with chronic glomerulonephritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Declining bone mass in men with chronic pulmonary disease: contribution of glucocorticoid treatment, body mass index, and gonadal function

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Risk of osteoporosis in men with chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Osteoporosis in steroid-dependent asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Osteoporosis in lung transplantation candidates with end-stage pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Use of inhaled corticosteroids and risk of fractures.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Glucocorticoid-induced osteopenia in adolescent heart transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Posttransplant bone disease: evidence for a high bone resorption state

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Osteoporosis and lung transplantation: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Long-term persistence of low bone density in orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Bone loss after renal transplantation: role of hyperparathyroidism, acidosis, cyclosporine and systemic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Factors influencing vertebral bone density after renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Osteoporosis after organ transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Evidence of continuing bone recovery at a mean of 7 years after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Osteoporosis prevention, diagnosis, and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990001-X

7 January 2021

10.1016/S0149-2918(04)90001-X

Identifiers

DOI

1 reference

9 August 2017

1 reference

PubMed ID

14996513